
In a recently published article, learn how #AptarPharma and Moine Recyclage are partnering to recover clean elastomer production scrap from injectable component manufacturing and repurpose it for durable technical applications. ow.ly/NEnX5107qLQ

We innovating and transform ideas into solutions that improve everyday life

In a recently published article, learn how #AptarPharma and Moine Recyclage are partnering to recover clean elastomer production scrap from injectable component manufacturing and repurpose it for durable technical applications. ow.ly/NEnX5107qLQ

The #NGP #pMDI conversation has moved from “when?” to “how?”. #AptarPharma’s webinar on November 30 will explore what’s changed, what it means for pMDI development & the practical decisions teams face. Choose your session: 10:00 or 16:00 CET. Register: ow.ly/T3VP5107csP

We're proud to share that Aptar has been named one of the World's Top Companies for Women 2026 by Forbes and Statista for the sixth consecutive year. Learn more about this recognition: ow.ly/QJ8c5106A43 #Aptar #BeYouBeAptar #Forbes #TopCompaniesForWomen

Aptar Pharma's Boonton, NJ, facility has received controlled substances registration, authorizing the handling, storage, manufacturing & testing of Schedule II-III controlled substances, expanding its capabilities for OINDPs. ow.ly/RKy05106iss

Choosing primary packaging for sensitive biologics means balancing product protection, manufacturing needs & supply continuity. Hear more from #AptarPharma & UCB at our November 19 webinar. Register: 🕘9AM GMT: ow.ly/5njG5105zFo 🕘3PM GMT: ow.ly/vsHC5105zBH

A new chapter for pulmonary drug delivery starts now. Welcome PULMOTREE and the Kolibri™ Non-Propellant Liquid Inhaler Platform to Aptar Pharma! Discover more:ow.ly/limW5104aMN #AptarPharma #PulmonaryDrugDelivery #Pulmotree #Kolibri

Read Aptar Pharma's blog exploring 5 trends shaping the future of #nasaldrugdelivery, as the conversation evolves beyond whether a therapy can be delivered nasally to where the nasal route can create meaningful value for patients & development programs: ow.ly/lXXs5102XE2

Registration is now open for #RDDEurope2027, April 27-30, Antibes, France, proudly co-organized by RDD Online® and #AptarPharma. Early Bird discounted registration is available until January 29, 2027 & the Poster Abstract deadline is January 15. More info: ow.ly/OJbm5102T0B

What if USP <382> could provide valuable development insights before formal validation begins? #AptarPharma’s latest article explores how a system-level approach can help identify potential risk drivers earlier. Read the full article: ow.ly/RUGS5102VAb #USP382 #Injectables

Aptar Reports Third Quarter 2026 Results. Learn more: ow.ly/sMac5102hBI

Aptar today announced that its Board of Directors declared a quarterly cash dividend of $0.50 per share. Learn more: ow.ly/3qbu5102he5

Thank you to @CrainsChicago for highlighting Virginie Maes’ appointment to Aptar Pharma President, effective January 1, 2027.
Aptar taps packaging executive to run pharma business chicagobusiness.com/health-c…

Aptar Pharma announces a collaboration with Stevanato Group, combining glass syringes & elastomer components to provide system-level data earlier in development & help inform packaging decisions for injectable therapies. ow.ly/XNLT5101gR5 #AptarPharma #Injectables

Aptar Pharma acquires PULMOTREE, expanding growth opportunities in next-generation #pulmonary #drugdelivery. The acquisition is expected to accelerate development and commercialization of the Kolibri™ Non-Propellant Liquid Inhaler. Full Press Release: ow.ly/POfG5101b2r

Join Aptar Pharma’s David Farrow on 2 Nov for a webinar exploring how molecular understanding, predictive science and in silico modelling can help inform formulation strategy for inhaled biologics. Register for one of two sessions: ow.ly/IqLA5100zRg

We are pleased to share that Virginie Maes has been appointed as President of Aptar Pharma, effective January 1, 2027. To learn more about the appointment, please visit our newsroom: ow.ly/W9QC5100kwi